Navigation Links
Chiltern Expands Its Global Reach to Latin America
Date:5/18/2008

LONDON, May 19 /PRNewswire/ -- Chiltern, a leading global research organization, announced the appointment of Mr. Oscar Podesta to the role of General Manager, Latin America.

The Latin American operation is expected to grow rapidly under the guidance of Mr. Podesta and will be primarily focused on supporting our Global Clinical Development brand. Mr. Podesta joins Chiltern with over 9 years experience in clinical research, where he has held executive positions in the CRO sector. Mr. Podesta will be responsible for the strategic development of Chiltern in the Latin American region.

"I am very pleased to join Chiltern at this exciting juncture for the company," commented Oscar Podesta, General Manager, Latin America. "Argentina and Brazil have long been considered the premier countries for clinical research in Latin America and the strong collaboration between sponsors, CROs, and academic organizations has created a large pool of highly qualified Investigators. Furthermore, regulatory authorities in Argentina (ANMAT) and Brazil (ANVISA) have taken an active role during the last 10 years in establishing a strong legal framework for the ethical conduct of clinical trials in the region, insuring that the highest possible clinical data is attained in accordance with both Good Clinical and Manufacturing practices."

"We are delighted that Oscar has joined Chiltern," said John Vann, Executive Vice President, Americas. "His strong background and experience in the region, in particular Argentina and Brazil, will be an asset for Chiltern as our strategic expansion in the region is expected to continue. Additionally, in recent months, there has been an increasing amount of interest from our sponsors to conduct trials in this part of the world, thus the time was right for Chiltern to establish operations in the region. Chiltern is now in a position to support all of its sponsors' needs throughout Latin America."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1,200 people with 23 offices across the Americas, Europe, Latin America and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier

Chiltern International, Inc.

2111 Palomar Airport Road

Suite 200

Carlsbad

CA 92011

USA

Tel: 1 (760) 707 5025

Fax: 1 (760) 707 5022

Email: Catherine.Lemercier@chiltern.com

Richard Baptista

Chiltern International Ltd.

171 Bath Road

Slough

Berkshire

SL1 4AA

UNITED KINGDOM

Tel: 44 (0) 1753 512 000

Fax: 44 (0) 1753 511 116

Email: Richard.Baptista@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Chiltern Announces New Expansion in Portugal
2. Chiltern Opens a New Office in Russia
3. Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CROs Meeting in Las Vegas, April 14 - 16, 2008.
4. Chiltern Wins Top Prize
5. Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
6. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
7. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
8. Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc.
9. Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
10. Marco Romano, MD Joins Chiltern as Medical Director, Europe
11. Ralphs Expands Discounted Generic Drug Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn from ... will show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , ... of pharmaceutical products, garnering increased attention from all stakeholders in the development of ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016   National Community Pharmacists Association ... MBA issued the following statement today in response to ... the Centers for Medicare & Medicaid Services (CMS) ... beneficiary advocates and others: patient advocacy organizations ... still reviewing the full CMS analysis. Our initial reaction ...
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas S.A. ... cash tender offer (the "Tender Offer") to purchase ... aggregate principal amount of its 6.500% Senior Notes ... Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection with ... "Consent Solicitation") consents (the "Consents") of the holders ...
Breaking Medicine Technology: